Dihomo-γ-Linolenic Acid in Patients with Atherosclerosis: Effects on Platelet Aggregation, Plasma Lipids and Low-Density Lipoprotein-Induced Inhibition of Prostacyclin Generation

A Szczeklik; R J Gryglewski; K Sladek; E Kostka-Trąbka; A Żmuda

doi:10.1055/s-0038-1661054

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1984; 51(02): 186-188
DOI: 10.1055/s-0038-1661054

Original Article

Schattauer GmbH Stuttgart

Dihomo-γ-Linolenic Acid in Patients with Atherosclerosis: Effects on Platelet Aggregation, Plasma Lipids and Low-Density Lipoprotein-Induced Inhibition of Prostacyclin Generation

A Szczeklik

The Department of Medicine, and Pharmacology, Copernicus Academy of Medicine, Cracow, Poland

,

R J Gryglewski

The Department of Medicine, and Pharmacology, Copernicus Academy of Medicine, Cracow, Poland

,

K Sladek

The Department of Medicine, and Pharmacology, Copernicus Academy of Medicine, Cracow, Poland

,

E Kostka-Trąbka

The Department of Medicine, and Pharmacology, Copernicus Academy of Medicine, Cracow, Poland

,

A Żmuda

The Department of Medicine, and Pharmacology, Copernicus Academy of Medicine, Cracow, Poland

› Author Affiliations

Abstract

PDF Download

Summary

Dihomo-γ-linolenic acid (DHLA), a precursor of monoenoic anti-aggregatory prostaglandins (PGE₁, PGD₂), was administered for 4 weeks in a daily dose of 1.0 g into 33 patients with atherosclerosis on a basis of a double-blind trial. Comparison of treatment and placebo groups revealed elevation of DHLA in red cell lipids in DHLA-treated subjects. No differences, however, between the two groups could be observed in platelet aggregability, thromboxane A₂ generation by platelets, serum cholesterol, PGE₁ and PGE₂ levels, and in inhibitory activity of low-density lipoproteins against prostacyclin synthetizing system in arteries. The dietary supplementation used did not lead to distinct antithrombotic effects.

Keywords

Atherosclerosis - Platelet aggregation - Dihomo-γ-linolenic acid

PDF (228 kb)

References

References
1 Szczeklik A, Gryglewski RJ, Musial J, Grodzińska L, Serwońska M, Marcinkiewicz E. Thromboxane generation and platelet aggregation in survivals of myocardial infarction. Thromb Haemostas 1978; 40: 66-74
2 Gryglewski RJ, Szczeklik A. Prostacyclin and atherosclerosis. In: Clinical Pharmacology of Prostacyclin. Lewis PJ, O’Grady J. (eds) Raven Press; New York: 1981. pp 89-95
3 Silver MJ, Hock W, Kocsis JJ, Ingerman CM, Smith JB. Arachidonic acid caused sudden death in rabbits. Science 1975; 183: 1085
4 Needleman P, Whitaker MO, Wyche A, Watters K, Sprecher H, Raz A. Manipulation of platelet aggregation by prostaglandins and their fatty acid precursors: pharmacological basis for a therapeutic approach. Prostaglandins 1980; 19: 165-181
5 Rose JC, Johnson M, Ramwell PW, Kot PA. Cardiovascular and platelet responses in the dog to the monoenoic prostaglandin precursor dihomo-γlinolenic acid (38727). Proc Soc Exp Biol Med 1975; 148: 1252-1256
6 Lagarde M, Burtin M, Dechavanne M, Sicard B, Coiffier B. Dihomo-gammalinolenic acid (20:3 ω 6) is more anti-aggregatory than eicosapentaenoic (20 :5 ω 3) in a platelet-endothelial cell mixture. Prostaglandins Med 1980; 4: 177-183
7 Gryglewski RJ, Salmon JA, Ubatuba SB, Weatherly BC, Moncada S, Vane JR. Effect of all CIS-5, 8, 11, 14, 17, eicosapentaenoic acid and PGH₃ on platelet aggregation. Prostaglandins 1979; 18: 453-478
8 Sim AK, McGraw AP. The activity of γ-linolenic and dihomo-γ-linolenate methyl esters in vitro and in vivo on blood platelet function in non-human primates and in man. Thromb Res 1977; 10: 385-388
9 Willis AL, Stone KJ, Hart M, Gibson V, Marples P, Botfield E, Comai K, Kuhn DC. Dietary fatty acids, prostaglandins, endoperoxides and the prevention of thrombosis. In: Prostaglandins in Hematology. Silver MJ, Smith JB, Kocsis JJ. (eds) Spectrum Publ Inc; Holiswood, New York: 1977. pp 371-390
10 Kernoff PB, Willis AL, Stone KJ, Davies JA, McNicol GP. Antithrombotic potential of dihomo-gamma-linolenic acid in man. Br Med J 1977; 2: 1441-1444
11 Dembińska-Kieć A, Zmuda A, Grodzińska L, Bieroń K, Basista M, Kedzior A, Kostka-Trabka E, Telesz. Zelazny T. Increased platelet activity after termination of prostacyclin infusion into man. Prostaglandins 1981; 21: 827-833
12 Wu KK, Hoak JC. A new method for the quantitative detection of platelet aggregates in patients with arterial insufficiency. Lancet 1974; 2: 923-926
13 Satoh K. Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method. Clin Chim Acta 1978; 90: 3743
14 Szczeklik A, Gryglewski RJ, Domagala B, Zmuda A, Hartwich J, Woźny E, Grzywacz M, Madej J, Gryglewska T. Serum lipoproteins, lipid peroxides and prostacyclin biosynthesis in patients with coronary heart disease. Prostaglandins 1981; 22: 795-807
15 Stone KJ, Willis AL, Hart M, Kirtland SJ, Kernoff PB, McNicol GP. The metabolism of dihomo-γ-linolenic acid in man. Lipids 1978; 14: 174-180
16 Renaud S, McGregor L, Morazain R, Thevenon C, Benoit C, Dumont E, Mendy F. Comparative beneficial effects on platelets functions and atherosclerosis of dietary linolenic and γ-linolenic acid in rabbits. Atherosclerosis 1982; 45: 43-51
17 Oelz O, Seyberth HW, Knapp Jr HR, Sweetman BJ, Oates JA. Effects of feeding ethyl-dihomo-γ-linolenate on prostaglandin biosynthesis and platelet aggregation in the rabbit. Biochim Biophys Acta 1976; 431: 268-277
18 Szczeklik A, Gryglewski RJ. Low-density lipoproteins (LDL) are carriers for lipid peroxides and invalidate prostacyclin biosynthese in arteries. Artery 1980; 7: 488-495
19 Nordøy A, Svensson B, Hoak J. The effects of albumin bound fatty acids on the platelet inhibitory function of human endothelial cells. Eur J Clin Invest 1979; 9: 5